-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Therapeutic Development and Current Uses of BCL-2 Inhibition

Program: General Sessions
Session: Ham-Wasserman Lecture
Saturday, December 5, 2020, 2:00 PM-3:00 PM

Andrew W Roberts, MBBS

Blood Cells and Blood Cancers, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Disclosures: Roberts: Servier: Research Funding; AbbVie: Research Funding; Genentech: Patents & Royalties: for venetoclax to one of my employers (Walter & Eliza Hall Institute); I receive a share of these royalties; Janssen: Research Funding.

OffLabel Disclosure: I will be discussing results of trials investigating venetoclax in several hematological malignancies, including multiple where the drug does not have a label.

See more of: Ham-Wasserman Lecture
See more of: General Sessions